期刊
ONCOTARGET
卷 6, 期 16, 页码 14209-14219出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3694
关键词
NSCLC; PD-L1; EGFR status; TKI; prognosis
资金
- National High Technology Research and Development Program of China [2012AA02A502]
- Innovative drug R&D center based on real-time high-throughput cell-based screening platform and large capacity compound library [2013ZX09401003-002]
- National Natural Science Funds of China [81372502, 81201917]
- Natural Science Foundation of Guangdong [S2013010016564]
- Specialized Research Fund for the Doctoral Program of Higher Education [20120171120116]
- Young Teacher Training Program of Sun Yat-Sen University [14ykpy38]
- Outstanding Young Talent Cultivation Project of Sun Yat-Sen University Cancer Center [04140701]
- Wu Jieping Medical Foundation Project [320.6750.131]
Backgrounds: Recent clinical trials have shown that immune-checkpoint blockade yields remarkable response in a subset of non-small cell lung cancer (NSCLC) patients. However, few studies directly focus on the association between epidermal growth factor receptor (EGFR) mutational status and programmed cell death-ligand 1 (PD-L1) expression. We examined whether PD-L1 is related to clinicopathologic factors and prognosis in patients with advanced NSCLC treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Methods: One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was examined by fluorescent quantitative polymerase chain reaction (PCR). The correlations between PD-L1 expression and EGFR status and survival parameters were analyzed. Results: The overall frequency of PD-L1 over-expression was 65.9% (112/170). In lung adenocarcinoma, PD-L1 tended to be associated with mutant EGFR (PD-L1 overexpression in mutant and wild-type EGFR, 64/89 (71.9%) vs. 32/56 (57.1%), respectively; p=0.067). Subgroup analyses showed that high PD-L1 expression was associated with significantly shorter overall survival (OS) in EGFR wild-type patients (p=0.029) but not in EGFR mutant patients (p=0.932) treated with EGFR-TKIs. Even more, for EGFR mutant patients, higher expression of PD-L1 might only signal better outcome with TKIs. Conclusions: High PD-L1 expression was likely to be associated with the presence of EGFR mutation in advanced lung adenocarcinoma. For EGFR wild-type patients, the PD-L1 over expression can be considered as a poor prognostic indicator of OS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据